Immix Biopharma, Inc. (company) announced effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors of the company appointed Yekaterina Chudnovsky as a member of the Board (appointment date). Ms. Chudnovsky will serve as a director for a term continuing until the Company?s 2024 annual meeting of stockholders and until her successor has been duly elected and qualified, or until her earlier resignation or removal. The Board has affirmatively determined that Ms. Chudnovsky qualifies as an ?independent director?

under the applicable Nasdaq Stock Market rules. Ms. Chudnovsky has served as General Counsel for an international privately-held technology firm since 2009, overseeing intellectual property, trademarks, technology acquisition, and mergers & acquisitions. Ms. Chudnovsky is Chairperson of the GI Research Foundation (GIRF) for the University of Chicago Digestive Diseases Center.

She has served on the GIRF board for the past 11 years, becoming President in 2019. Her work with GIRF contributes to raising over $3 million annually to support the physicians and scientists at the University of Chicago and beyond. Ms. Chudnovsky is an active board member of XCures and has served as a member of the board of Elicio Therapeutics, Inc., since October 2022.

Ms. Chudnovsky has a particular interest in cancer research and personalized cancer vaccines, and is a frequent investor and donor in the space. Prior to her current roles, she began her legal career at Thomas Coburn Fagel Haber, with a focus on corporate law, real estate, mergers and acquisitions, bankruptcy, and business banking. Ms. Chudnovsky received a B.A. in political science and Slavic literature from Northwestern University, and a J.D. from DePaul University.

Ms. Chudnovsky was appointed to the Board pursuant to the Securities Purchase Agreement. Pursuant to the Securities Purchase Agreement, the Company agreed to increase the size of the Board and to appoint Ms. Chudnovsky to serve until the Company?s 2024 annual meeting of stockholders and until her successor has been duly elected and qualified or her earlier resignation or removal.